Bayer Aktiengesellschaft

Claus Weisemann

Hans-Georg Rast

Wolfgang Kreiss

Erich Brendel

Patrick Bosch&eacute;

Guenther Eberz

Ernst Chantraine

Roland Rupp

Venkata-Rangarao Kanikanti

Michael Eisele

Stefan Kettelhoit

G&uuml;nther Eberz

Hans Friedrich Mahler

Ranga-Rao Kanikanti

This application claims a method for detecting biologically active substances, comprising the following steps

Method and device for detecting biologically active substances

The invention claimed herein is a kit for detecting biologically active substances on a support, comprising the luminescent marine bacteriain a form stabilized for transport and storage, one or more cultivation media or the individual components of cultivation media for the microorganism wherein the cultivation media containsmg/l tomg/l of aspartic acid, and optionally additives for extending the period of luminescence selected from N-acylhomoserine lactones, dipeptides, oligopeptides, or their biochemical precursors, and boron compounds.

The present invention relates to orally administrable multiple-unit sustained-release dose forms having controlled agitation-independent release of active compound and processes for their production using a selected erodable hydrophilic polymer (HPC) and a limitation of the maximum size of the active compound-containing polymer particles to &lE;3 mm.

Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

The present invention relates to a pharmaceutical preparation for oral administration which comprises moxifloxacin, its salt and/or hydrate and lactose, to a process for its preparation, and to the use of this preparation for controlling bacterial infections in humans and animals.

Pharmaceutical moxifloxacin preparation

This invention relates to an orally administered osmotic drug release system that consists of a shell and a core containing a pharmaceutically active substance, as well as a process for its production. The invention relates further to an osmotic drug release system for use as a drug in human beings and animals, as well as the use of the osmotic drug release system in the production of a drug for the treatment and/or prevention of illnesses in human beings and animals.

Osmotic medicament releasing system

The mixture to be tested for toxic components is first separated into fractions by chromatography. The separated fractions are then contacted with luminescent microorganisms in the chromatographic system itself and the toxicity of the fractions is determined by measurement of the bioluminescence. The chromatographic separation may be carried out either by thin layer chromatography or by column liquid chromatography.

Growing community of inventors

Apex, NC, United States of America

Claus Weisemann